FDA Approves Thermo Fisher CDx for Glioma Treatment with VORANIGO
Thermo Fisher’s CDx for identifying glioma patients eligible for treatment with Servier Pharmaceuticals’ VORANIGO gets FDA approval.
Read MorePosted by Andy Lundin | Oct 21, 2024 | Unknown Origin & Other Cancer Types |
Thermo Fisher’s CDx for identifying glioma patients eligible for treatment with Servier Pharmaceuticals’ VORANIGO gets FDA approval.
Read MorePosted by Andy Lundin | Oct 17, 2024 | Sepsis |
A microfluidic chip-based method assesses sepsis severity by analyzing immune cell migration: a new approach to diagnosis and prognosis.
Read MorePosted by Andy Lundin | Oct 15, 2024 | Cardiovascular |
The Atellica IM Troponin I test received clearance for predicting cardiac events after initial symptoms of acute coronary syndrome.
Read MorePosted by Chris Wolski | Oct 11, 2024 | Molecular Diagnostic Analyzers |
Two case studies illustrate how a newly developed sepsis test improves turnaround times and diagnostic accuracy.
Read MorePosted by Chris Wolski | Oct 10, 2024 | Sequencing Systems |
Reducing the incidence of healthcare-associated infections, and the antimicrobial resistance they can trigger, is critical for patient care.
Read More